Viruses, Vol. 16, Pages 494: Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis

Viruses, Vol. 16, Pages 494: Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis Viruses doi: 10.3390/v16040494 Authors: Xiaoqin Le Yinzhong Shen Tuberculosis is one of the most common opportunistic infections and a prominent cause of death in patients with human immunodeficiency virus (HIV) infection, in spite of near-universal access to antiretroviral therapy (ART) and tuberculosis preventive therapy. For patients with active tuberculosis but not yet receiving ART, starting ART after anti-tuberculosis treatment can complicate clinical management due to drug toxicities, drug–drug interactions and immune reconstitution inflammatory syndrome (IRIS) events. The timing of ART initiation has a crucial impact on treatment outcomes, especially for patients with tuberculous meningitis. The principles of ART in patients with HIV-associated tuberculosis are specific and relatively complex in comparison to patients with other opportunistic infections or cancers. In this review, we summarize the current progress in the timing of ART initiation, ART regimens, drug–drug interactions between anti-tuberculosis and antiretroviral agents, and IRIS.
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research